Pharmaceutical Analysis

The United States Food and Drug Administration (FDA) has issued a new guidance document, Analytical Procedures and Method Validation for Drugs and Biologics. The guidance is quite general in nature. Anyone hoping for specific recommendations on topics such as which methods to use will be disappointed. Industry experts say that i really isn’t feasible for the FDA to provide detailed recommendations about analytical methods for biopharmaceuticals, however.

This installment provides an overview of high-throughput characterization techniques of drug leads to support small molecule drug discovery programs in a pharmaceutical company. A myriad of analytical chemistry techniques including separation science methodologies are used to confirm the structures and identities, quantitating the concentrations of stock solutions, and measuring key physicochemical properties of the new chemical entities (NCE). A case study is used here to illustrate the details of these applications in high-throughput characterization.

Here in part II of our series on assessing protein aggregation, we provide an overview of best practices for achieving this goal, including the importance of using a multimethod approach.Here in part II of our series on assessing protein aggregation, we provide an overview of best practices for achieving this goal, including the importance of using a multimethod approach.

This installment provides an overview of modern practices of high-throughput purification to support small-molecule drug discovery.

Benedetto Natalini of the University of Perugia, Italy, spoke to Bethany Degg of The Column about the driving forces in pharmaceutical analysis, including the importance of regulation, chirality, and miniaturization.

Experimental results and method validation data from two analytical case studies of complex small?molecule pharmaceuticals illustrates the utility and advantages of UHPLC in high-resolution separations.

Most analytical approaches used for the determination of low-molecular-weight noncovalent aggregates in protein pharmaceuticals suffer from important limitations. This first part of this two-part column series discusses those limitations.

In this installment, we discuss fluorescence-detection size exclusion chromatography (FSEC) technology and its implications in protein characterization, specifically the development and characterization of biologics.  

A discussion of the role of the gradient in separation by reversed-phase and ion-exchange HPLC, with data from two products to illustrate the key points

During the past year, LCGC examined current trends in the application of liquid chromatography (LC), and gas chromatography (GC), and related techniques in environmental, food, forensics, and pharmaceutical analysis. This article presents some developments made by separation scientists working in these application areas and offers insights into the current trends in each field.

The modern usage and specific applications of HILIC for two other major classes of analytes - glycopeptides and glycoproteins - are discussed.

Agilent Technologies

Answers to common questions about HILIC, and an overview of its application to biopharmaceutical analysis.

LCGC recently spoke with Pauline Rudd of University College, Dublin, and The National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, about her work using ultrahigh-pressure liquid chromatography (UHPLC) for the characterization of protein glycosylation.

The use of a monolithic column reduces analysis time in an on-line biopharmaceutical HPLC analysis of granulocyte colony stimulating factor.

Recent advances in sampling techniques in the pharmaceutical industry sparked significant interest in applying improvements to extraction methods for greater analyte detection and quantitation.

A method using HR-MS systems to characterize the structures of metabolites is presented. The result is a general workflow for metabolism studies in drug discovery and development.

Click here to view the complete E-Separation Solutions newsletter from August 22, 2013.

A set of extended chiral separation screens using HPLC and SFC has been tailored to meet the specific and changing needs of customers in a pharmaceutical development setting.

HPLC method development can be accelerated by using three distinct method templates of increasing complexity.

Pharmaceutical Analysis Technology Forum

Click here to view the complete E-Separation Solutions newsletter from May 23, 2013.

This article highlights some selected examples of the power of liquid chromatography combined with mass spectrometry (LC–MS) in the development of protein biopharmaceuticals.

The determination of genotoxic impurities (GIs) in drug substances and pharmaceutical products is an emerging topic in pharmaceutical quality control. GIs are intermediates or reactants in the synthetic pathway of a drug substance and should be monitored at ppm (?g/g drug substance) or even ppb (ng/g) levels. This is several orders of magnitude lower than in classical impurity analysis (0.05% or 500 ppm level) or in residual solvent analysis. Analytical methods for the determination of GIs include gas chromatography (GC) and liquid chromatography (LC), both often combined with mass spectrometry (MS) detection. Some typical examples of GIs trace analysis using GC and LC are presented. The potential of on-line reaction monitoring is also discussed.

This article provides an overview of the most recent advances in the field of chiral and achiral separations in SFC. This involves research focused on the most critical parameters in SFC separations, but also on practical issues such as the serial coupling of columns.